EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for the First-Line Treatment of Advanced Renal Cell Carcinoma in Europe

HEMEL HEMPSTEAD, England, June 23, 2017 -- (Healthcare Sales & Marketing Network) -- EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the European Medicines Agency's Committ... Biopharmaceuticals, Oncology, Regulatory EUSA Pharma, FOTIVDA, tivozanib, renal cell carcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news